

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

December 31, 2019

	Shares	Value
COMMON STOCKS[†] - 99.6%		
Biotechnology - 74.6%		
Amgen, Inc.	70,408	\$ 16,973,257
Gilead Sciences, Inc.	205,949	13,382,566
Vertex Pharmaceuticals, Inc.*	48,968	10,721,544
Biogen, Inc.*	34,907	10,357,954
Illumina, Inc.*	30,183	10,012,908
Regeneron Pharmaceuticals, Inc.*	24,348	9,142,187
Alexion Pharmaceuticals, Inc.*	62,758	6,787,278
Seattle Genetics, Inc.*	54,348	6,209,803
Incyte Corp.*	69,062	6,030,494
BioMarin Pharmaceutical, Inc.*	65,189	5,511,730
Exact Sciences Corp.*	54,080	5,001,318
Alnylam Pharmaceuticals, Inc.*	43,220	4,977,647
Ionis Pharmaceuticals, Inc.*	68,098	4,113,800
Guardant Health, Inc.*	47,760	3,731,966
Medicines Co.*	43,376	3,684,357
ACADIA Pharmaceuticals, Inc.*	84,199	3,602,033
Arrowhead Pharmaceuticals, Inc.*	54,150	3,434,735
Amarin Corporation plc ADR ^{1,1}	158,184	3,391,465
Mirati Therapeutics, Inc.*	25,770	3,320,722
Exelixis, Inc.*	187,138	3,297,372
Immunomedics, Inc.*	145,426	3,077,214
Bluebird Bio, Inc.*	35,020	3,073,005
Intercept Pharmaceuticals, Inc.*	23,709	2,938,019
Blueprint Medicines Corp.*	35,730	2,862,330
United Therapeutics Corp.*	31,496	2,774,168
Nektar Therapeutics ^{*,1}	127,101	2,743,475
FibroGen, Inc.*	61,427	2,634,604
BeiGene Ltd. ADR [*]	15,230	2,524,525
PTC Therapeutics, Inc.*	50,500	2,425,515
Ultragenyx Pharmaceutical, Inc.*	52,980	2,262,776
Myriad Genetics, Inc.*	73,643	2,005,299
Ligand Pharmaceuticals, Inc. — Class B ^{*,1}	17,911	1,867,938
Sage Therapeutics, Inc.*	20,116	1,452,174
Total Biotechnology		166,326,178
Pharmaceuticals - 21.5%		
AbbVie, Inc.	190,933	16,905,208
Mylan N.V.*	237,240	4,768,524
Sarepta Therapeutics, Inc.*	34,818	4,492,915
Neurocrine Biosciences, Inc.*	41,689	4,481,151
PRA Health Sciences, Inc.*	34,040	3,783,546
Jazz Pharmaceuticals plc*	22,375	3,340,140
Global Blood Therapeutics, Inc.*	39,923	3,173,479
Alkermes plc*	128,360	2,618,544
Agios Pharmaceuticals, Inc.*	53,228	2,541,637
Portola Pharmaceuticals, Inc.* ¹	76,620	1,829,685
Total Pharmaceuticals		47,934,829
Healthcare-Products - 1.9%		
Bio-Techne Corp.	18,808	4,128,544
Healthcare-Services - 1.6%		
Syneos Health, Inc.*	59,620	3,545,900
Total Common Stocks		221,935,451
(Cost \$120,445,113)		
RIGHTS^{†††} - 0.0%		
BIOTECHNOLOGY - 0.0%		
Clinical Data, Inc.* ²	24,000	—
Total Rights		—
(Cost \$—)		
Face Amount		
REPURCHASE AGREEMENTS^{††3} - 0.7%		
J.P. Morgan Securities LLC issued 12/31/19 at 1.53% due 01/02/20	\$ 977,768	977,768
Barclays Capital, Inc. issued 12/31/19 at 1.40% due 01/02/20	315,277	315,277
BofA Securities, Inc. issued 12/31/19 at 1.50% due 01/02/20	315,277	315,277
Total Repurchase Agreements		1,608,322
(Cost \$1,608,322)		
Shares		
SECURITIES LENDING COLLATERAL^{†,4} - 2.3%		
Money Market Fund		
First American Government Obligations Fund — Class Z, 1.47% ⁵	5,042,581	5,042,581
Total Securities Lending Collateral		5,042,581
(Cost \$5,042,581)		
Total Investments - 102.5%		\$ 228,586,354
(Cost \$127,096,016)		
Other Assets & Liabilities, net - (2.5)%		(5,668,960)
Total Net Assets - 100.0%		\$ 222,917,394

* Non-income producing security.

[†] Value determined based on Level 1 inputs.

^{††} Value determined based on Level 2 inputs.

^{†††} Value determined based on Level 3 inputs.

¹ All or a portion of this security is on loan at December 31, 2019.

² Security was fair valued by the Valuation Committee at December 31, 2019. The total market value of fair valued securities amounts to \$0, (cost \$0) or 0.0% of total net assets.

³ Repurchase Agreements.

⁴ Securities lending collateral.

⁵ Rate indicated is the 7-day yield as of December 31, 2019.

ADR — American Depositary Receipt

plc — Public Limited Company